Sichenzia Ross Ference Kesner LLP Represents MabVax Therapeutics Holdings, Inc. in $5 Million Registered Direct Offerings
Press Release – New York, NY – November 15, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, in a series of registered direct offerings of common stock and preferred stock for aggregate gross proceeds of approximately $5,000,000.
The offerings were consummated in August, September and October 2017. The Sichenzia Ross Ference Kesner LLP team was led by partners Harvey Kesner, Avital Perlman and Tara Guarneri-Ferrara and associate Evan Berger.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Founding Partner Marc Ross Speaks at Benzinga Cannabis Capital Conference - August 15, 2018
- Founding Partner Gregory Sichenzia Featured in the Media Discussing Scrutiny of Elon Musk’s Twitter Communications - August 15, 2018
- Founding Partner Gregory Sichenzia Featured on Business Insider Discussing Elon Musk’s Tweets and Securities Legality - August 8, 2018